Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 826 to 850 of 1152 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
861 increased mutation (MESH:D009154) 1669: Increased, DNA damage and mutation
864 increased abnormal DNA repair (MP:0008058) DNA repair complex (GO:1990391) 1669: Increased, DNA damage and mutation
865 increased cell proliferation (GO:0008283) mesothelial cell (CL:0000077) 870: Increase, Cell Proliferation
866 increased Neoplasm of the lung (HP:0100526) lung (UBERON:0002048) 1670: Lung cancer
867 increased increased lung tumor incidence (MP:0008014) lung (UBERON:0002048) 1670: Lung cancer
868 increased pattern recognition receptor signaling pathway (GO:0002221) 1495: Substance interaction with the lung resident cell membrane components
869 increased toll-like receptor signaling pathway (GO:0002224) Toll-like receptor (PR:000001096) 1495: Substance interaction with the lung resident cell membrane components
870 increased toll-like receptor 4 signaling pathway (GO:0034142) Toll-like receptor 4 (PR:000001155) 1495: Substance interaction with the lung resident cell membrane components
871 increased Malignant mesothelioma (HP:0100001) mesothelioma (MESH:D008654) 1090: Increased, mesotheliomas
872 occurrence receptor binding (GO:0005102) angiotensin-converting enzyme 2 (PR:000003622) 1739: Binding to ACE2
876 occurrence membrane fusion (GO:0061025) transmembrane protease serine 2 (PR:000016456) 1738: SARS-CoV-2 cell entry
877 occurrence endocytosis involved in viral entry into host cell (GO:0075509) cathepsin L1 (human) (PR:P07711) 1738: SARS-CoV-2 cell entry
878 decreased type I interferon signaling pathway (GO:0060337) interferon alpha (PR:000024938) 1901: Interferon-I antiviral response, antagonized by SARS-CoV-2
879 decreased type I interferon signaling pathway (GO:0060337) interferon beta (PR:000024939) 1901: Interferon-I antiviral response, antagonized by SARS-CoV-2
880 occurrence cellular response to exogenous dsRNA (GO:0071360) RNA viral genome (GO:0019022) 1901: Interferon-I antiviral response, antagonized by SARS-CoV-2
883 decreased regulation of receptor activity (GO:0010469) smoothened (PR:000015288) 2027: Antagonism, Smoothened receptor
885 decreased protein import into nucleus, translocation (GO:0000060) zinc finger protein GLI1 (PR:000008026) 2028: Decrease, GLI1/2 translocation to nucleus
886 decreased protein import into nucleus, translocation (GO:0000060) zinc finger protein GLI2 (PR:000008027) 2028: Decrease, GLI1/2 translocation to nucleus
889 decreased gene expression (GO:0010467) zinc finger protein GLI1 (PR:000008026) 2040: Decrease, GLI1/2 target gene expression
890 decreased gene expression (GO:0010467) zinc finger protein GLI2 (PR:000008027) 2040: Decrease, GLI1/2 target gene expression
894 increased Cleft palate (HP:0000175) 2042: Increase, Orofacial clefting
895 increased cleft upper lip (MP:0005170) 2042: Increase, Orofacial clefting
897 decreased protein localization to cilium (GO:0061512) smoothened (PR:000015288) 2044: Decrease, Smoothend relocation and activation
898 decreased decreased triiodothyronine level (MP:0005473) 3,3',5'-triiodothyronine (CHEBI:28774) 1003: Decreased, Triiodothyronine (T3)
900 occurrence blood vessel remodeling (GO:0001974) blood vessel (UBERON:0001981) 2069: Occurrence, Abnormal Vascular Remodeling